Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$125.59 +1.5%	$125.96	$110.04 ▼ $238.00	$18.40B	0.12	1.38 million shs	1.80 million shs
IONS Ionis Pharmaceuticals	$33.56 +1.7%	$30.55	$23.95 ▼ $52.34	$5.25B	0.15	1.56 million shs	893,963 shs
NBIX Neurocrine Biosciences	$121.02 +0.6%	$107.02	$84.23 ▼ $157.98	$11.98B	0.26	1.13 million shs	970,641 shs
UTHR United Therapeutics	$305.35 +0.5%	$299.95	$264.33 ▼ $417.82	$13.77B	0.58	443,023 shs	518,041 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	+6.25%	+5.88%	-8.55%	-46.63%
IONS Ionis Pharmaceuticals	0.00%	+4.03%	+18.17%	+8.12%	-14.41%
NBIX Neurocrine Biosciences	0.00%	+4.59%	+19.37%	+5.22%	-14.77%
UTHR United Therapeutics	0.00%	+1.30%	+7.24%	-17.60%	+11.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.922 of 5 stars	4.2	5.0	3.7	3.5	2.5	1.9
IONS Ionis Pharmaceuticals	4.5067 of 5 stars	4.3	1.0	3.0	4.2	3.3	0.6
NBIX Neurocrine Biosciences	4.949 of 5 stars	4.4	3.0	2.9	4.0	2.5	3.1
UTHR United Therapeutics	4.9925 of 5 stars	4.3	4.0	4.6	3.5	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$191.30	52.32% Upside
IONS Ionis Pharmaceuticals	2.65	Moderate Buy	$56.67	68.85% Upside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$162.00	33.86% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$392.00	28.38% Upside

Current Analyst Ratings Breakdown

Latest IONS, BIIB, UTHR, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/6/2025	NBIX Neurocrine Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/6/2025	NBIX Neurocrine Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$137.00 ➝ $145.00
5/6/2025	NBIX Neurocrine Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $154.00
5/6/2025	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$137.00 ➝ $152.00
5/6/2025	NBIX Neurocrine Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$96.00 ➝ $115.00
5/6/2025	NBIX Neurocrine Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$155.00 ➝ $165.00
5/6/2025	NBIX Neurocrine Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$138.00 ➝ $139.00
5/6/2025	NBIX Neurocrine Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$158.00 ➝ $160.00
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/5/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.82B	1.87	$20.62 per share	6.09	$114.71 per share	1.09
IONS Ionis Pharmaceuticals	$717.25M	7.45	N/A	N/A	$3.70 per share	9.07
NBIX Neurocrine Biosciences	$2.41B	4.96	$3.52 per share	34.35	$25.97 per share	4.66
UTHR United Therapeutics	$2.99B	4.60	$18.36 per share	16.63	$127.35 per share	2.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	11.22	7.61	1.51	16.87%	14.98%	8.76%	N/A
IONS Ionis Pharmaceuticals	-$366.29M	-$2.99	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	N/A
NBIX Neurocrine Biosciences	$341.30M	$2.95	36.78	18.70	0.77	14.49%	13.38%	9.73%	N/A
UTHR United Therapeutics	$984.80M	$25.06	13.41	11.11	0.97	40.31%	19.22%	16.15%	7/30/2025 (Estimated)

Latest IONS, BIIB, UTHR, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
2/26/2025	Q4 2024	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/19/2025	Q4 2024	IONS Ionis Pharmaceuticals	-$1.12	-$0.66	+$0.46	-$0.66	$140.97 million	$227.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
IONS Ionis Pharmaceuticals	2.12	8.47	8.82
NBIX Neurocrine Biosciences	N/A	3.40	3.28
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
IONS Ionis Pharmaceuticals	93.86%
NBIX Neurocrine Biosciences	92.59%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
IONS Ionis Pharmaceuticals	2.60%
NBIX Neurocrine Biosciences	4.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
IONS Ionis Pharmaceuticals	800	159.16 million	153.62 million	Optionable
NBIX Neurocrine Biosciences	1,200	98.97 million	95.42 million	Optionable
UTHR United Therapeutics	980	45.11 million	39.33 million	Optionable

IONS, BIIB, UTHR, and NBIX Headlines

Recent News About These Companies

OMERS ADMINISTRATION Corp Has $2.58 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

May 17 at 5:41 AM | marketbeat.com

Lazard Asset Management LLC Sells 4,795 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 17 at 5:24 AM | marketbeat.com

Interesting UTHR Put And Call Options For July 18th

May 16 at 10:36 PM | nasdaq.com

MPM Bioimpact LLC Makes New $8.12 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)

May 16 at 8:39 AM | marketbeat.com

Parkman Healthcare Partners LLC Cuts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 16 at 8:30 AM | marketbeat.com

Ethic Inc. Makes New $959,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

May 16 at 4:44 AM | marketbeat.com

Construction underway for new United Therapeutics facility in Stewartville

May 15 at 9:49 PM | kttc.com

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central

May 15 at 11:47 AM | finance.yahoo.com

Mubadala Investment Co PJSC Invests $2.39 Million in United Therapeutics Co. (NASDAQ:UTHR)

May 15 at 6:48 AM | marketbeat.com

Janus Henderson Group PLC Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

May 15 at 5:27 AM | marketbeat.com

Deutsche Bank AG Purchases 14,132 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 15 at 4:46 AM | marketbeat.com

Bank of America Corp DE Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

May 15 at 4:02 AM | marketbeat.com

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses

May 14, 2025 | finance.yahoo.com

Investment Management Corp of Ontario Has $10.55 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

May 13, 2025 | marketbeat.com

Hudson Bay Capital Management LP Acquires 34,810 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 13, 2025 | marketbeat.com

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Has $1.96 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 13, 2025 | marketbeat.com

BNP Paribas Financial Markets Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

May 13, 2025 | marketbeat.com

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics | LQDA Stock News

May 12, 2025 | gurufocus.com

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Therapeutics | LQDA Stock News

May 12, 2025 | gurufocus.com

Liquidia Faces Patent Infringement Lawsuit by United Therapeutics

May 12, 2025 | tipranks.com

United Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by Gotham Asset Management LLC

May 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
By Ryan Hasson | May 5, 2025
View Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
By Thomas Hughes | May 14, 2025
View SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
Analysts and Institutions Continue to Bet Big on Alphabet
By Ryan Hasson | May 16, 2025
View Analysts and Institutions Continue to Bet Big on Alphabet
Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
By Jeffrey Neal Johnson | May 14, 2025
View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch

IONS, BIIB, UTHR, and NBIX Company Descriptions

Biogen NASDAQ:BIIB

$125.59 +1.89 (+1.53%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$123.94 -1.65 (-1.31%)

As of 05/16/2025 07:15 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Ionis Pharmaceuticals NASDAQ:IONS

$33.56 +0.57 (+1.73%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$33.57 +0.01 (+0.03%)

As of 05/16/2025 06:04 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Neurocrine Biosciences NASDAQ:NBIX

$121.02 +0.75 (+0.62%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$116.10 -4.91 (-4.06%)

As of 05/16/2025 05:10 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$305.35 +1.43 (+0.47%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$304.99 -0.36 (-0.12%)

As of 05/16/2025 05:10 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time